Medco Buys DNA Direct To Bolster Personalized Medicine Business
This article was originally published in The Gray Sheet
Executive Summary
Medco's purchase of DNA Direct, announced Feb. 2, will enable the pharmacy benefits manager to grow its personalized medicine business by adding decision support services for payors, providers and patients
You may also be interested in...
Medco: Market Multiplier for Personalized Medicine
Medco is developing data that could accelerate the adoption of personalized medicine--as a way to make itself more relevant to customers and the lives they represent. Armed with infrastructure from its mail pharmacy business and access to medical information on large groups of people, it is financing and conducting studies to show the value of pharmacogenomic tests in improving clinical outcomes. By so doing, it could become an incredible enabler of companies pursuing personalized medicine.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.